Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapies for endocrine conditions and neurodegenerative diseases. Its lead asset is avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 (LUCIDITY trial) for post-bariatric hypoglycemia. Additional pipeline includes AMX0035 (Wolfram syndrome, Phase 2), AMX0114 (ALS, Phase 1), and AMX0318 (PBH, preclinical), all targeting high unmet medical needs with no currently approved therapies.
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-086645 | EDGAR | 99K words |
| 2025-03-04 | 2024-12-31 | 0000950170-25-031309 | EDGAR | 98K words |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018447 | EDGAR | 122K words |
| 2023-03-13 | 2022-12-31 | 0000950170-23-007609 | EDGAR | 121K words |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005157 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-336682 | EDGAR | 71K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-268059 | EDGAR | 72K words |
| 2025-08-07 | 2025-06-30 | 0001193125-25-174948 | EDGAR | 70K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066363 | EDGAR | 66K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-122833 | EDGAR | 72K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093311 | EDGAR | 70K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056269 | EDGAR | 64K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061516 | EDGAR | 79K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041335 | EDGAR | 77K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021369 | EDGAR | 73K words |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024465 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016883 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-08 | 0001193125-26-385331 | EDGAR | 1K words |
| 2026-08-20 | 0001193125-26-359418 | EDGAR | 21K words |
| 2026-08-18 | 0001193125-26-354793 | EDGAR | 2K words |
| 2026-08-18 | 0001193125-26-354716 | EDGAR | 2K words |
| 2026-08-06 | 0001193125-26-336670 | EDGAR | 3K words |
| 2026-03-24 | 0001193125-26-120691 | EDGAR | 7K words |
| 2026-03-03 | 0001193125-26-086629 | EDGAR | 3K words |
| 2026-01-08 | 0001193125-26-006991 | EDGAR | 7K words |
| 2025-11-06 | 0001193125-25-268043 | EDGAR | 3K words |
| 2025-09-10 | 0001193125-25-200159 | EDGAR | 20K words |
83 total filings indexed. 56 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001658551 |
| Ticker | AMLX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.amylyx.com |
| Listed | 2022-01-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AMLX (~200 tokens, structured JSON with cryptographic provenance)